Dusigitumab
Chemical compound
- none
- 1204390-13-5
- 7749
- none
- 0Z70DT5PRX
- D10352
Dusigitumab is a human monoclonal antibody designed for the treatment of cancer. It binds to IGF2.[1][2] It was developed by MedImmune, which was acquired by AstraZeneca, using Xenomouse technology licensed from Abgenix.[3] Its development has been discontinued.[2]
References
- ^ "Dusigitumab" (PDF). Statement On A Nonproprietary Name Adopted By The USAN Council. American Medical Association.
- ^ a b Osher E, Macaulay VM (August 2019). "Therapeutic Targeting of the IGF Axis". Cells. 8 (8): 895. doi:10.3390/cells8080895. PMC 6721736. PMID 31416218.
- ^ "Dusigitumab - MedImmune". AdisInsight. Springer Nature Switzerland AG.
- v
- t
- e
Monoclonal antibodies for tumors
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e